Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) (NCT05519449)

🧪 Interventions in This Study

• JANX007 (BIOLOGICAL)
• Darolutamide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (36 Sites)

Showing the first 25 of 36 sites.

• University of Alabama at Birmingham Hospital — Birmingham, Alabama
• Mayo Clinic — Phoenix, Arizona
• USC Norris Comprehensive Cancer Center — Los Angeles, California
• UCLA Department of Medicine — Los Angeles, California
• Hoag Memorial Hospital Presbyterian — Newport Beach, California
• University of California Davis Comprehensive Cancer Center — Sacramento, California
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
• Yale New Haven Hospital — New Haven, Connecticut
• Mayo Clinic — Jacksonville, Florida
• University of Chicago Medical Center — Chicago, Illinois
• University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
• University of Minnesota Medical Center — Minneapolis, Minnesota
• Mayo Clinic — Rochester, Minnesota
• Washington University School of Medicine — St Louis, Missouri
• Northwell Health R.J. Zuckerberg Cancer Hospital — Lake Success, New York
• NYU Langone Health Long Island — Mineola, New York
• NYU Langone Health — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Weill Cornell Medicine — New York, New York
• Montefiore Medical Center — The Bronx, New York
• University of Cincinnati Medical Center — Cincinnati, Ohio
• The Ohio State University — Columbus, Ohio
• Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
• Thomas Jefferson University Honickman Center — Philadelphia, Pennsylvania
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania

📞 Contact the Study Coordinator

Phone: (858) 206-8471

Email: psma-007-001_ct.gov@januxrx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostate Cancer

• A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
• A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
• Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
• A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
• Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland

Explore by condition: All Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.